DBV Technologies S.A. (DBVT) Financial Analysis & Valuation | Quarter Chart
DBV Technologies S.A. (DBVT)
DBVTPrice: $20
Fair Value: 🔒
🔒score
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergie... more
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and devel... more
Description
Shares
| Market Cap | $478.43M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | FR | CEO | Daniel Tassé |
| IPO Date | 2014-10-22 | CAGR | 0.2% |
| Employees | 106 | Website | www.dbv-technologies.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
DBVT chart loading...
Fundamentals
Technicals
| Enterprise Value | $561.81M | P/E Ratio | -3.9 |
| Forward P/E | -91.19 | PEG Ratio | — |
| P/S Ratio | 917.57 | P/B Ratio | 4.64 |
| P/CF Ratio | -6.43 | P/FCF Ratio | -5.65 |
| EPS | $-5.2 | EPS Growth 1Y | -2.54% |
| EPS Growth 3Y | -7.26% | EPS Growth 5Y | -61.02% |
| Revenue Growth 1Y | -100% | Gross Margin | -10.43% |
| Operating Margin | -200.17% | Profit Margin | -195.5% |
| ROE | -1.89% | ROA | -0.63% |
| ROCE | -0.86% | Current Ratio | 3.67 |
| Quick Ratio | 3.67 | Cash Ratio | 3.35 |
| Debt/Equity | 0.13 | Interest Coverage | -135.92 |
| Altman Z Score | 0.71 | Piotroski Score | 2 |